{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:45:43Z","timestamp":1773294343441,"version":"3.50.1"},"reference-count":91,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2006,6,12]],"date-time":"2006-06-12T00:00:00Z","timestamp":1150070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Child Psychology Psychiatry"],"published-print":{"date-parts":[[2006,9]]},"abstract":"<jats:p>\n                    <jats:bold>Background:\u2002<\/jats:bold>\n                    The use of psychotropic medication to treat children and adults with mental retardation (MR) has a long and extensive history. There are no identified medications to address specific cognitive deficits among persons with MR. Instead, psychotropic medications are used to treat specific behavioral symptoms and\/or psychiatric syndromes. The purpose of this review is to provide an overview of the recent literature regarding the use of psychotropic medications in this population, focusing primarily on children and adolescents.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:\u2002<\/jats:bold>\n                    The paper is divided into five general drug categories: psychostimulants, antipsychotics, antidepressants, mood stabilizers, and other drugs. Each section offers an overview of the research supporting the use of that class of medications in children and adolescents with MR as well as cautions regarding potential side effects. Finally, specific clinical recommendations are offered.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:\u2002<\/jats:bold>\n                    The majority of studies in MR tend to be open trials, case reports, or controlled studies with small samples. The available data suggests that persons with MR respond to various psychotropic medications in ways similar to the typically developing population. However, rates of response tend to be poorer and the occurrence of side effects tends to be more frequent.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:\u2002<\/jats:bold>\n                    The use of psychotropic medications in children and adolescents with MR requires even greater monitoring and the use of lower doses and slower dosage increases than in the general population.\n                  <\/jats:p>","DOI":"10.1111\/j.1469-7610.2006.01588.x","type":"journal-article","created":{"date-parts":[[2006,6,12]],"date-time":"2006-06-12T10:53:31Z","timestamp":1150109611000},"page":"871-882","source":"Crossref","is-referenced-by-count":73,"title":["Practitioner Review: Psychopharmacology in children and adolescents with mental retardation"],"prefix":"10.1111","volume":"47","author":[{"given":"Benjamin L.","family":"Handen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Gilchrist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,6,12]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2779(1999)5:4<279::AID-MRDD5>3.0.CO;2-6"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1089\/104454603321666171"},{"key":"e_1_2_8_4_1","first-page":"198","article-title":"Pharmacotherapy of disorders in mental retardation","volume":"1","author":"Aman M.G.","year":"2000","journal-title":"European Child and Adolescent Psychiatry"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199307000-00022"},{"key":"e_1_2_8_6_1","first-page":"521","article-title":"Fenfluramine and methylphenidate in children with mental retardation and borderline IQ: Clinical effects","volume":"101","author":"Aman M.G.","year":"1997","journal-title":"American Journal of Mental Retardation"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2779(1999)5:4<253::AID-MRDD2>3.0.CO;2-R"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199103000-00013"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.8.1337"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/pmj.79.929.139"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2788.1998.00144.x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2003.00047.x"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0112"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199610000-00018"},{"key":"e_1_2_8_15_1","first-page":"481","article-title":"Psychotropic medication use in people with developmental disabilities","volume":"46","author":"Curtis J.L.","year":"1997","journal-title":"Maryland Medical Journal"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1352\/0895-8017(1998)102<0427:PTOAAS>2.0.CO;2"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.2002.tb00266.x"},{"key":"e_1_2_8_18_1","first-page":"85","volume-title":"The international consensus handbook: Psychotropic medications and developmental disabilities","author":"DesNoyers Hurley A.","year":"1998"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D144"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2788.2003.00464.x"},{"key":"e_1_2_8_21_1","first-page":"77","article-title":"A double\u2010blind, placebo\u2010controlled study of the efficacy of transdermal clonidine in autism","volume":"53","author":"Fankhauser M.","year":"1992","journal-title":"Journal of Clinical Psychiatry"},{"key":"e_1_2_8_22_1","unstructured":"FDA Public Health Advisory October 15 2004."},{"key":"e_1_2_8_23_1","unstructured":"FDA Talk Paper(August 5 2005).1 PV 3758 AMP STRATTERA\u00ae (atomoxetine HCl) DESCRIPTION STRATTERA\u00ae (atomoxetine HCl) is a selective norepinephrine reuptake inhibitor. Atomoxetine HCl is \u2026http:\/\/www.fda.gov\/medwatch\/SAFETY\/2005\/MAY_PI\/Strattera_PI.pdf."},{"key":"e_1_2_8_24_1","volume-title":"Clinical pediatric neurology: A signs and symptoms approach","author":"Fenichel G.M.","year":"1997"},{"key":"e_1_2_8_25_1","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1177\/070674370104600807","article-title":"Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities","volume":"46","author":"Friedlander R.","year":"2001","journal-title":"Canadian Journal of Psychiatry"},{"key":"e_1_2_8_26_1","first-page":"314","article-title":"Clinical evaluation of treatment with fluvoxamine, a selective serotonin reuptake inhibitor in children with autistic disorder","volume":"33","author":"Fukuda T.","year":"2001","journal-title":"No to Hattatsu [Brain and Development]"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(93)90737-6"},{"key":"e_1_2_8_28_1","volume-title":"Child and adolescent clinical psychopharmacology","author":"Green W.H.","year":"2001"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200102000-00012"},{"key":"e_1_2_8_30_1","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1542\/peds.86.6.922","article-title":"Efficacy of Ritalin among mentally retarded children with ADHD","volume":"86","author":"Handen B.L.","year":"1990","journal-title":"Pediatrics"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199205000-00011"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199103000-00012"},{"key":"e_1_2_8_33_1","first-page":"411","volume-title":"Treatment of childhood disorders","author":"Handen B.L.","year":"2006"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199410000-00014"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02578399"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02684955"},{"key":"e_1_2_8_37_1","article-title":"Open label, prospective trial of olanzapine in adolescents with subaverage intelligence and disruptive behavioral disorders","author":"Handen B.L.","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"e_1_2_8_38_1","volume-title":"Journal of Pediatric Neurology","author":"Hardan A."},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2779(1999)5:4<270::AID-MRDD4>3.0.CO;2-I"},{"key":"e_1_2_8_40_1","volume-title":"Long\u2010term safety and adverse events of risperidone in children, adolescents, and adults with MR\/DD","author":"Hellings J.A.","year":"2004"},{"key":"e_1_2_8_41_1","first-page":"333","article-title":"Sertraline response in adults with mental retardation and autistic disorder","volume":"57","author":"Hellings J.A.","year":"1996","journal-title":"Journal of Clinical Psychiatry"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1089\/10445460152595559"},{"key":"e_1_2_8_43_1","article-title":"A crossover study of risperidone in children, adolescents and adults with mental retardation","author":"Hellings J.A.","journal-title":"Journal of Autism Developmental Disorders"},{"key":"e_1_2_8_44_1","volume-title":"Handbook of psychiatric drug therapy","author":"Hyman S.E.","year":"1995"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n1018"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199210000-00005"},{"key":"e_1_2_8_47_1","volume-title":"Medical genetics","author":"Jorde L.B.","year":"1995"},{"key":"e_1_2_8_48_1","volume-title":"Psychiatric drug treatment","author":"Kaplan H.I.","year":"1993"},{"key":"e_1_2_8_49_1","first-page":"S18","article-title":"Long\u2010term therapy of bipolar illness","author":"Keck P.E.","year":"2003","journal-title":"Journal of Family Practice"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.3109\/10401230309085675"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0031-3955(05)70068-7"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.1998.8.107"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.52.8.1105"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1177\/0145445501251004"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1056-4993(18)30143-3"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511543920.007"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.1999.9.99"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2788.1997.05252.x"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa013171"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1352\/0895-8017(2005)110<48:POEIAW>2.0.CO;2"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2788.2000.00306.x"},{"key":"e_1_2_8_62_1","volume-title":"Efficacy of fluvoxamine in children with autistic disorder","author":"McDougle C.J.","year":"1998"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199802000-00010"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200208000-00010"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1996.01830110037005"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612043383872"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-200302000-00015"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199902000-00004"},{"key":"e_1_2_8_69_1","unstructured":"Physician's desk reference.(2004). Oradell NJ:Medical Economics Co."},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1089\/1044546041649084"},{"key":"e_1_2_8_71_1","first-page":"567","article-title":"Emotional disturbance and mental retardation: Diagnostic overshadowing","volume":"86","author":"Reiss A.","year":"1982","journal-title":"American Journal of Mental Deficiency"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2788.1999.00193.x"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2000.10.27"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07059-7"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199607000-00012"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.1997.7.255"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199407000-00022"},{"key":"e_1_2_8_78_1","first-page":"179","volume-title":"The international consensus handbook: Psychotropic medications and developmental disabilities","author":"Sovner R.","year":"1998"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n1209"},{"key":"e_1_2_8_80_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D147"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.1997.7.9"},{"key":"e_1_2_8_82_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2004.14.455"},{"key":"e_1_2_8_83_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-19838"},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.2000.tb00083.x"},{"key":"e_1_2_8_85_1","first-page":"373","article-title":"Fluoxetine and aggression","volume":"16","author":"Troisi A.","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"e_1_2_8_86_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.110.3.e34"},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1089\/104454601750143348"},{"key":"e_1_2_8_88_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2788.1999.043005349.x"},{"key":"e_1_2_8_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(01)00546-6"},{"key":"e_1_2_8_90_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2788.2000.00284.x"},{"key":"e_1_2_8_91_1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0022-3565(25)33153-8","article-title":"A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain","volume":"222","author":"Wong D.T.","year":"1982","journal-title":"Journal of Pharmacology and Experimental Therapy"},{"key":"e_1_2_8_92_1","doi-asserted-by":"publisher","DOI":"10.1352\/0895-8017(2004)109<310:EORODB>2.0.CO;2"}],"container-title":["Journal of Child Psychology and Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1469-7610.2006.01588.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acamh.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1469-7610.2006.01588.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:14:17Z","timestamp":1762186457000},"score":1,"resource":{"primary":{"URL":"https:\/\/acamh.onlinelibrary.wiley.com\/doi\/10.1111\/j.1469-7610.2006.01588.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,12]]},"references-count":91,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["10.1111\/j.1469-7610.2006.01588.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1469-7610.2006.01588.x","archive":["Portico"],"relation":{},"ISSN":["0021-9630","1469-7610"],"issn-type":[{"value":"0021-9630","type":"print"},{"value":"1469-7610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6,12]]}}}